Drug class
Anti-von Willebrand factor (vWF) nanobody; antithrombotic biologic
Mechanism of action
Binds the A1 domain of von Willebrand factor and blocks its interaction with platelet glycoprotein Ib, reducing vWF-mediated platelet adhesion and platelet consumption in acquired thrombotic thrombocytopenic purpura.
General use cases
- Treatment of acquired thrombotic thrombocytopenic purpura (aTTP) in adults and paediatric patients aged 12 years and older, in combination with plasma exchange and immunosuppressive therapy; not a substitute for these standard treatments
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
